España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Avidity Biosciences
RNA
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$30.70
-2.04
-6.23%
At close: -
$30.70
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Avidity Biosciences (RNA) Forecast
News
Earnings
Avidity Biosciences (RNA) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Avidity Biosciences (NASDAQ:RNA) Stock
Avidity Biosciences Stock (NASDAQ: RNA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, November 26, 2024
RBC Capital Initiates Coverage On Avidity Bio...
Benzinga Newsdesk
Wednesday, November 13, 2024
Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk
Avidity Biosciences shares are trading higher...
Benzinga Newsdesk
Assessing Avidity Biosciences: Insights From 10 Financial Analysts
Benzinga Insights
Needham Reiterates Buy on Avidity Biosciences...
Benzinga Newsdesk
Tuesday, November 12, 2024
Avidity Biosciences Says It Is Opening Up New...
Benzinga Newsdesk
Thursday, November 07, 2024
Avidity Biosciences Q3 EPS $(0.65) Beats $(0....
Benzinga Newsdesk
Thursday, October 31, 2024
Needham Reiterates Buy on Avidity Biosciences...
Benzinga Newsdesk
Wednesday, October 30, 2024
Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk
Avidity Biosciences Pursues Potential Acceler...
Benzinga Newsdesk
Monday, October 21, 2024
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences
Benzinga Insights
Evaluating Avidity Biosciences: Insights From 10 Financial Analysts
Benzinga Insights
TD Cowen Maintains Buy on Avidity Biosciences...
Benzinga Newsdesk
Monday, October 07, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Thursday, October 03, 2024
Avidity Biosciences FDA Removed Partial Clini...
Benzinga Newsdesk
Tuesday, September 24, 2024
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Vandana Singh
Goldman Sachs Initiates Coverage On Avidity B...
Benzinga Newsdesk
Wednesday, September 18, 2024
Cantor Fitzgerald Reiterates Overweight on Av...
Benzinga Newsdesk
Monday, September 16, 2024
Unveiling 7 Analyst Insights On Avidity Biosciences
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Av...
Benzinga Newsdesk
Monday, September 09, 2024
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on Av...
Benzinga Newsdesk
Wednesday, August 28, 2024
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings)
Benzinga Insights
Barclays Initiates Coverage On Avidity Biosci...
Benzinga Newsdesk
Monday, August 26, 2024
Evercore ISI Group Maintains Outperform on Av...
Benzinga Newsdesk
Thursday, August 15, 2024
Reported Earlier, Avidity Biosciences Prices ...
Benzinga Newsdesk
Wednesday, August 14, 2024
Avidity Biosciences shares are trading lower ...
Benzinga Newsdesk
Tuesday, August 13, 2024
Avidity Biosciences Proposes $250M Public Off...
Benzinga Newsdesk
Needham Reiterates Buy on Avidity Biosciences...
Benzinga Newsdesk
Monday, August 12, 2024
The Analyst Landscape: 7 Takes On Avidity Biosciences
Benzinga Insights
Evercore ISI Group Maintains Outperform on Av...
Benzinga Newsdesk
Friday, August 09, 2024
Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk
Avidity Biosciences Q2 EPS $(0.65) Beats $(0....
Benzinga Newsdesk
Avidity Biosciences shares are trading higher...
Benzinga Newsdesk
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Avidity Biosciences Says Data Suggest del-zot...
Benzinga Newsdesk
Friday, August 02, 2024
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)
Michael Juliano
Monday, July 01, 2024
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
Piero Cingari
Thursday, June 20, 2024
(RNA) - Analyzing Avidity Biosciences's Short Interest
Benzinga Insights
Sunday, June 16, 2024
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
Lekha Gupta
Friday, June 14, 2024
Adobe, Avidity Biosciences And 3 Stocks To Watch Heading Into Friday
Avi Kapoor
Reported Earlier, Avidity Biosciences Prices ...
Benzinga Newsdesk
Thursday, June 13, 2024
Avidity Up 33% on Rare Muscle Disease Study Results
Zacks
B of A Securities Maintains Buy on Avidity Bi...
Benzinga Newsdesk
Wednesday, June 12, 2024
Avidity Bioscience Announces Proposed Public ...
Benzinga Newsdesk
Needham Maintains Buy on Avidity Biosciences,...
Benzinga Newsdesk
Crude Oil Moves Higher; Vera Bradley Shares Slide
Avi Kapoor
Chardan Capital Maintains Buy on Avidity Bios...
Benzinga Newsdesk
Evercore ISI Group Maintains Outperform on Av...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch